Search results
Showing 51 to 100 of 8162 results
Our tool to help you plan for and implement NICE guidance. View upcoming guidance and understand the impact of guidance on your resources.
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.
Our board sets out our strategic priorities and policies.
We estimate the costs or savings (budget impact) associated with technologies and guidelines so you can plan for and implement guidance.
The Patient Access Schemes Liaison Unit (PASLU) works with companies who are considering a patient access scheme for their drug or treatment. Patient
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services....
NICE has published final draft guidance that does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.
Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)
This guideline covers recognising, diagnosing and managing vitamin B12 deficiency in people aged 16 and over, including deficiency caused by autoimmune gastritis. It also covers monitoring for gastric cancer in people with autoimmune gastritis.
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
We want you to tell us what matters to you, your organisation or your community.
To help us understand the needs of our users we are offering the opportunity to be directly involved in the work we do. Fellows, registrars and...
We're excited that you're interested in joining a committee and helping us improve health and social care services. By joining, you'll have the...
Digital technologies for managing non-specific low back pain: early value assessment (HTE16)
Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over....
View recommendations for HTE16Show all sections
A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent womb cancer in final draft NICE guidance published today.
Admission rates due to heart failure in people with diabetes
Admission rates due to heart failure in people with diabetes Subject(s): Diabetes Date of publication: 01 August
All our committees include experienced professionals with knowledge of a particular topic within health or social care . Professional members also...
Find out more about being on a committee at NICE.
A public consultation on our new approach to prioritising guidance is now open
Running for 4 weeks, the consultation seeks your views about our plans to make topic selection and prioritisation more integrated, effective and timely.
Support for industry to engage with NICE during all stages of health technology development
Achieving and demonstrating compliance with NICE TA and HST guidance
The NHS and patients need evidence that commissioners are funding medicines and treatments approved through the NICE Technology Appraisal (TA) or...
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
PDAs help people decide on healthcare options. They provide evidence-based information on the options available, along with likely outcomes, benefits,
Our indicators measure outcomes that reflect quality of care. They also look at processes that are linked by evidence to improved outcomes. All our...
Our diagnostics assessment recommendations are prepared by an independent advisory committee called the diagnostics advisory committee (DAC). Standing
The quality standards advisory committees (QSAC) are independent committees that help to develop our quality standards . Come to a meeting Committee
Evidence-based recommendations on endoscopic sleeve gastroplasty for obesity. This involves using an endoscopic device to fold the stomach in on itself and stitch it together to reduce its volume.
View recommendations for IPG783Show all sections
Help us improve NICE: take part in research to help us develop better products and services.
Up to 14,000 people could benefit from the first treatment for severe alopecia recommended by NICE
New one-a-day tablet for people with severe hair loss due to alopecia areata recommended by NICE
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Highly specialised technologies evaluation committee members
Highly specialised technologies evaluation committee members
Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.
The methods, processes and topic selection manuals cover: how we choose medicines and other health technologies to evaluate (topic selection) the...
Putting our guidance into practice benefits patients and carers, healthcare professionals and organisations. Teams within NICE have a role in...
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
Help make a difference on behalf of the people most affected by our recommendations. The voluntary and community sector forum brings together...
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee. This is called the highly specialised
NICE is trialling an innovative new approach to the way digital products, devices and diagnostics are assessed.
This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.
We want to better understand views and experiences of NICE, from our audiences.
The different types of health, public health and social care information provided by NICE.
NICE guidance that could generate cost savings.
Biosimilar technologies: NICE position statement - information for the public
Biosimilar medicines – NICE's approach A biological medicine is any medicinal product made by or derived from a biological (natural) source, for...
NICE has been collaborating with NHS England on the Chemotherapy Dose Standardisation initiative which has been developed by the Medicines...
There are 2 different points of the lifecycle of a NICE Technology Appraisal at which consideration of reference to or inclusion of a biosimilar is...
Patients taking part in clinical trials may receive drugs which have been evaluated by NICE technology appraisal guidance. Queries have been raised...
On this page, you'll find all our position statements relating to technology appraisals. Biosimilar technologies: NICE position statement Biosimilar
Tools and resources to help you implement guidance and quality standards at work.
We work with organisations to help to put our guidance into practice. We work with NHS, local authority and other organisations in their area,...
Please note, from April 2023 NICE will no longer produce Medtech Innovation Briefings (MIBs) on behalf of NHS England. MIBs were commissioned by NHS...
NICE transparency of spend